OIPE JC181 APR 26 2004 PATENT & TRADEMARK OFFICE

PATENTS

IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Applicants: Comess, et al.

Serial No.: 10/681,784

Filed: October 8, 2003

Title: SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY

Case No.: 6983US02

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: April 22, 2004

Tanya Parent 4/22/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled: SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY are the following:

1. Information Disclosure Statement;
2. Form PTO-1449, in duplicate;
3. References as cited on PTO-1449 (31 references); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,
Comess, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

OIPE JC161
APR 26 2004
PATENT & TRADEMARK OFFICE

PATENTS

IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Applicants: Comess, et al.

Serial No.: 10/681,784

Filed: October 8, 2003

Title: SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY

Case No.: 6983US02

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: April 22, 2004

Tanya Parent 4/22/04

Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Documents listed in this Information Disclosure Statement, were first cited in a communication from a Foreign Patent Office by the European Patent Office in a counterpart international PCT application. This Information Disclosure Statement is being filed within three month of the mailing date of that communication.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,
Comess, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

OIPE JC681 APR 2 6 2004 PATENT & TRADEMARK OFFICE

DATE: April 22, 2004 SHEET _1_ of _2_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6983US02	SERIAL NO. 10/681,784
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) Comess, et al.	
(Use several sheets if necessary)	FILING DATE October 8, 2003	GROUP 1614
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
/ES/	A1	2,335,221		Ewins et al.			
/ES/	A2	6,207,704	03/27/2001	Liu et al.	514	475	06/08/1998

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO
/ES/	B1	272 351		AT				
/ES/	B2	686 644		DE				
/ES/	B3	2001-240581		JP				
/ES/	B4	98/16503	23.04.1998	WO				
/ES/	BB	98/16506	23.04.1998	WO				
/ES/	B6	98/16514	23.04.1998	WO				
/ES/	B7	98/16520	23.04.1998	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

/ES/	C1	J. Med. Chem. 33(5):1312-1329 (1990) XP002271724
/ES/	C2	J. Org. Chem. 53(7):1380-1383 (1988) XP002271725
/ES/	C3	Bull. Chem. Soc. Jpn. 40:2844-2847 (1967) XP002271726
/ES/	C4	J. Chem. Soc. Perkin Trans. I 1602-1605 (1973) XP002271727
/ES/	C5	Synthesis, 4:280-282 (1989) XP002271728
/ES/	C6	Chem. Ber. 76:128-134 (1943) XP002271729
/ES/	C7	J. Am. Chem. Soc. 67:1711 (1945) XP002271730
/ES/	C8	Nippon Kagaku Kaishi 723-727 (1978) XP002271731
/ES/	C9	J. Chem. Soc. 961-966 (1950) XP002271732
/ES/	C10	Synthesis 6:487-489 (1981) XP002271733
/ES/	C11	J. Med. Chem. 24(9):1097-1099 (1981) XP002271734
/ES/	C12	Heterocycl. Chem. 30(6):1613-1622 (1993) XP002271736

APR 2 6 2004
PATENT & TRADEMARK OFFICE

/ES/	C13	Chem. Heterocycl. Compd. 8:557-561 (1972) XP002271737
/ES/	C14	Chem. Heterocycl. Compd. 7:964-967 (1971) XP002271738
/ES/	C15	Chem. Heterocycl. Compd. 8:1212-1215 (1972) XP002271739
/ES/	C16	Chem. Pharm. Bull. 41(5):894-906 (1993) XP002271740
/ES/	C17	J. Org Chem. 38:1512-1517 (1973) XP002271741
/ES/	C18	J. Chem. Soc. Perkin Trans. I 2313-2318 (1973) XP002271742
/ES/	C19	Tetrahedron 44(5):1465-1476 (1988) XP002271743
/ES/	C20	J. Am. Chem. Soc. 109(21):6491-6502 (1987) XP002271744
/ES/	C21	JP 2001-240581 XP002271745
/ES/	C22	Proceedings of the National Academy of Sciences of the United States of America 99(15):10066-10071 (2002) XP002271723

EXAMINER	/Ebenezer Sackey/ (09/04/2008)	**DATE CONSIDERED**

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

OIPE JC181 APR 2 6 2004 PATENT & TRADEMARK OFFICE

DATE: April 22, 2004 SHEET _1_ of _2_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	6983US02	10/681,784
	APPLICANT(S) Comess, et al.	
(Use several sheets if necessary)	FILING DATE October 8, 2003	GROUP 1614
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
/ES/	A1	2,335,221		Ewins et al.			
/ES/	A2	6,207,704	03/27/2001	Liu et al.	514	475	06/08/1998

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO
/ES/	B1	272 351		AT				
/ES/	B2	686 644		DE				
/ES/	B3	2001-240581		JP				
/ES/	B4	98/16503	23.04.1998	WO				
/ES/	BB	98/16506	23.04.1998	WO				
/ES/	B6	98/16514	23.04.1998	WO				
/ES/	B7	98/16520	23.04.1998	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

/ES/	C1	J. Med. Chem. 33(5):1312-1329 (1990) XP002271724
/ES/	C2	J. Org. Chem. 53(7):1380-1383 (1988) XP002271725
/ES/	C3	Bull. Chem. Soc. Jpn. 40:2844-2847 (1967) XP002271726
/ES/	C4	J. Chem. Soc. Perkin Trans. I 1602-1605 (1973) XP002271727
/ES/	C5	Synthesis, 4:280-282 (1989) XP002271728
/ES/	C6	Chem. Ber. 76:128-134 (1943) XP002271729
/ES/	C7	J. Am. Chem. Soc. 67:1711 (1945) XP002271730
/ES/	C8	Nippon Kagaku Kaishi 723-727 (1978) XP002271731
/ES/	C9	J. Chem. Soc. 961-966 (1950) XP002271732
/ES/	C10	Synthesis 6:487-489 (1981) XP002271733
/ES/	C11	J. Med. Chem. 24(9):1097-1099 (1981) XP002271734
/ES/	C12	Heterocycl. Chem. 30(6):1613-1622 (1993) XP002271736

OIPE JC181 APR 2 6 2004 PATENT & TRADEMARK OFFICE

/ES/	C13	Chem. Heterocycl. Compd. 8:557-561 (1972) XP002271737
/ES/	C14	Chem. Heterocycl. Compd. 7:964-967 (1971) XP002271738
/ES/	C15	Chem. Heterocycl. Compd. 8:1212-1215 (1972) XP002271739
/ES/	C16	Chem. Pharm. Bull. 41(5):894-906 (1993) XP002271740
/ES/	C17	J. Org Chem. 38:1512-1517 (1973) XP002271741
/ES/	C18	J. Chem. Soc. Perkin Trans. I 2313-2318 (1973) XP002271742
/ES/	C19	Tetrahedron 44(5):1465-1476 (1988) XP002271743
/ES/	C20	J. Am. Chem. Soc. 109(21):6491-6502 (1987) XP002271744
/ES/	C21	JP 2001-240581 XP002271745
/ES/	C22	Proceedings of the National Academy of Sciences of the United States of America 99(15):10066-10071 (2002) XP002271723

EXAMINER	/Ebenezer Sackey/ (09/04/2008)	**DATE CONSIDERED**	

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)